Clinical benefit was also observed in the large Phase III RATIFY trial in AML patients regardless of their FLT3 mutant: FLT3 wt ratio and the type of FLT3 mutation they harboured.6 Based on this, a multinational, randomized Phase III clinical trial has commenced, investigating the efficacy of midostaurin in combination with chemotherapy and also as single‐agent maintenance therapy in newly diagnosed AML patients harbouring wt FLT3.34 Here, FLT3 is linked to acute myeloid leukemia.